Kadimastem, an Israel-based regenerative medicine company, agreed to expand a stem cell-based drug screening collaboration with Merck Serono that started in 2012. The partnership focuses on developing compounds to differentiate stem cells into oligodendrocytes, or brain cells that produce myelin, which are destroyed by the immune system in multiple sclerosis.

Full Story:

Related Summaries